Junshi CEO Ning Li (Junshi)
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Early this month, the FDA handed Junshi Biosciences an agency first: A breakthrough designation for a PD-(L)1 therapy out of China. Now, the Shanghai …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
